Showing results (421-430 of 513) with videos related to
Sort By:
Pageof 52
Patient Preference and Adherence|July 2, 2020
Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country StudyDaniel Aletaha, M Elaine Husni, Joseph F Merola, et al.Journal of the American Academy of Dermatology|December 20, 2023
Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasisAndrew Blauvelt, Phoebe Rich, Howard Sofen, et al.Journal of the American Academy of Dermatology|June 23, 2020
Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology HospitalistsOmid Zahedi Niaki, Milan J Anadkat, Steven T Chen, et al.Lancet (London, England)|February 10, 2020
Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trialChristopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, et al.Online Journal of Public Health Informatics|October 22, 2019
The design and evaluation of a Bayesian system for detecting and characterizing outbreaks of influenzaNicholas E Millett, John M Aronis, Michael M Wagner, et al.Journal of Biomedical Informatics|August 12, 2017
A Bayesian system to detect and characterize overlapping outbreaksJohn M Aronis, Nicholas E Millett, Michael M Wagner, et al.The British Journal of Dermatology|April 15, 2018
A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi processL Thorlacius, J R Ingram, B Villumsen, et al.Lupus Science & Medicine|March 4, 2021
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skinJoseph F Merola, Wenting Wang, Carrie G Wager, et al.Dermatology and Therapy|November 25, 2021
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis RegistryJessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, et al.RMD Open|October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 studyIain B McInnes, Koji Kato, Marina Magrey, et al.Pageof 52